Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Inc.

In a report released today, Joe Laetsch from Morgan Stanley maintained a Buy rating on HF Sinclair Corporation, with a price target of $49.35. Laet...

Morgan Stanley Keeps Their Buy Rating on HF Sinclair Corporation (DINO)

An announcement from Hino Motors ( ($JP:7205) ) is now available. Hino Motors has approved the sale of its entire 2.0% stake in Taiwan-based HOTAI ...

Hino Motors to Sell Hotai Motor Stake to Toyota, Booking ¥30 Billion Extraordinary Gain

Gaucho Group Holdings ( ($VINO) ) has shared an announcement. On January 15, 2026, Gaucho Group Holdings provided a corporate update to its stockho...

Gaucho Group issues investor presentation corporate update

In a report released today, from Wells Fargo maintained a Hold rating on HF Sinclair Corporation, with a price target of $58.00. In addition to Wel...

Wells Fargo Remains a Hold on HF Sinclair Corporation (DINO)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Inovio Pharmaceuticals, with a price target of $6.00. Ten...

Current Quarter	$-0.37	Next Quarter	$-0.34
Current Year	$-1.98	Next Year	$-1.26
QoQ Growth	+8.1%	YoY Growth	+36.4%
3Y EPS CAGR	+39.0%	Target Price	$7.63
Consensus	Buy	Upside	+348.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INO	$1.70	0.00%	989.45K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INO	$1.70	0%	989.45K
3
4
5
6

INO

INO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Inovio Pharmaceuticals Inc. Data in Excel

Get Inovio Pharmaceuticals Inc. Data in Excel